The FDA has granted accelerated approval to Datroway for adults with previously-treated, locally advanced or metastatic EGFR-mutated NSCLC.

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

A new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...

The FDA has blessed AstraZeneca and Daiichi Sankyo’s Datroway to treat patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...

Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and platinum chemotherapy.

DATROWAY ® has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR- mutated non-small cell lung cancer who have received prior EGFR- directed ...

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

DATROWAY is approved in more than 30 countries worldwide for the treatment of adult patients with unresectable or metastatic HR-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) ...

DATROWAY was administered by intravenous infusion once every three weeks. The median duration of treatment was 6.7 months (range: 0.7 months to 16.1 months) for patients who received DATROWAY.

DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who ...